Key Insights

Highlights

Treatment Research

1 treatments under study, led by Trs005

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Not Yet Recruiting1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06886139Phase 2Not Yet RecruitingPrimary

A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

Showing all 1 trials

Research Network

Common Treatments

  • Trs0051

Active Sponsors

  • Zhejiang Teruisi Pharmaceutical Inc.1

Top Investigators

  • yuankai shi, MD1

    Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Activity Timeline